Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 15/20 | 0.60 |
| ▸ | MEN1 | O00255 | 15/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 15/20 | 0.60 |
| ▸ | RAB9A | P51151 | 13/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ATM | Q13315 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CASP1 | P29466 | 2/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | STAT1 | P42224 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047234 | 0.85 | MEN1 (0.79) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL13379899 | 0.82 | NPC1 (0.65) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL13290988 | 0.79 | NPC1 (0.60) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL3040313 | 0.79 | NPC1 (0.81) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL13290989 | 0.79 | NPC1 (0.81) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL10759780 | 0.79 | NPC1 (0.81) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL3033496 | 0.78 | ALOX5 (0.50) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL8995917 | 0.77 | KDM4E (0.67) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL3028821 | 0.76 | PPARG (0.46) | NPC1MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL3219297 | 0.75 | NPC1 (1.00) | NPC1MEN1KMT2ARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090321646-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID(S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2009-12-31 | — | — | US | claimed |
| EP-1904828-A4 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | AUSTRALIAN WINE RES INST (AU) | 2008-11-19 | — | — | EP | claimed |
| EP-1904828-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | The Australian Wine Research Institute (AU) | 2008-04-02 | — | — | EP | claimed |
| WO-2007006099-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2007-01-18 | — | — | WO | claimed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090321646-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID(S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2009-12-31 | — | — | US | disclosed |
| EP-1904828-A4 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | AUSTRALIAN WINE RES INST (AU) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1904828-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | The Australian Wine Research Institute (AU) | 2008-04-02 | — | — | EP | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007006099-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | APP, BACE1, BACE2 | NPC1 160/4885MEN1 1639/4885KMT2A 4034/4885 |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | NPC1 160/4885MEN1 1639/4885KMT2A 4034/4885 |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | NPC1 160/4885MEN1 1639/4885KMT2A 4034/4885 |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | NPC1 160/4885MEN1 1639/4885KMT2A 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.